Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
31630831
DOI
10.1016/j.chroma.2019.460615
PII: S0021-9673(19)31022-2
Knihovny.cz E-zdroje
- Klíčová slova
- Experimental design, Impurities, LC-MS/MS, Method operable design region, Nintedanib, Quality by Design,
- MeSH
- chromatografie kapalinová metody MeSH
- indoly analýza chemie MeSH
- metoda Monte Carlo MeSH
- pravděpodobnost MeSH
- reprodukovatelnost výsledků MeSH
- řízení kvality MeSH
- riziko MeSH
- rozpouštědla MeSH
- tandemová hmotnostní spektrometrie metody MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- indoly MeSH
- nintedanib MeSH Prohlížeč
- rozpouštědla MeSH
Nintedanib (NIN) is a tyrosine kinase inhibitor recently approved for the treatment of idiopathic pulmonary fibrosis. As a new drug, no monograph is available so far in official compendia. A liquid chromatography-tandem mass spectrometry method is presented for the simultaneous determination of NIN and its seven potential impurities. The risk-based approach of Analytical Quality by Design was applied in method development. The critical method parameters (CMPs) were the type of organic solvent in the mobile phase, formic acid percentage, column flow rate, oven temperature, gradient slope of organic eluent. The critical method attributes (CMAs) were selected as analysis time and selectivity between the main compound NIN and the adjacent peaks. Design of Experiments methodology was effectively employed for establishing the relationship between the CMPs and the CMAs. In the scouting step, a Restek Ultra AQ C18 (100 × 2.1 mm, 2.7 µm) core-shell column was selected, and then the effects of different levels of the five CMPs on the CMAs were evaluated by means of a 35//16 symmetric screening matrix. A Box-Behnken Design made it possible to obtain detailed maps of predicted CMAs throughout the investigated experimental domain, pointing out the presence of interaction and quadratic effects. The probability of meeting the specifications for the CMAs was calculated by Monte-Carlo simulations, performing a risk analysis and drawing risk of failure maps, which were used to visualize and define the method operable design region (MODR) with a probability π ≥ 90%. The final working conditions (enclosing the MODR interval) were as follows: methanol as organic solvent; formic acid percentage, 0.15% v/v; flow rate, 0.40 mL min-1 (0.37-0.43 mL min-1); oven temperature, 40 °C (38-40 °C); gradient slope of organic eluent, 14.00% eluent B min-1 (12.85-15.15% eluent B min-1). The resulting analysis time was about 10 min. Validation was carried out according to International Council for Harmonisation guidelines and the optimized method was applied to the analysis of NIN soft capsules for quality control purposes.
Department of Pharmacy and Biotechnology University of Bologna Via Belmeloro 6 40126 Bologna Italy
Mass Spectrometry Center University of Florence Viale G Pieraccini 6 50139 Florence Italy
Zentiva k s Praha U Kabelovny 130 102 37 Praha 10 Czech Republic
Citace poskytuje Crossref.org